FDA Asks: Better Drug Trial Paperwork or Same Old Headache?
Published Date: 3/13/2026
Notice
Summary
The FDA wants your thoughts on how it collects info about new drug tests before they’re approved. This affects drug companies and researchers who submit applications to test new medicines. You’ve got until May 12, 2026, to share your comments, helping shape smoother, clearer rules without extra costs or delays.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
Large IND Reporting Burden
If you sponsor or run clinical drug trials, you must follow 21 CFR part 312 reporting and recordkeeping rules that FDA estimates generate millions of hours of annual burden: for human drugs FDA lists 152,856 total responses and 23,016,423 total annual hours, and for biologics FDA lists 48,179 total responses and 6,694,050 total annual hours.
New RWE/RWD Tracking Fields
Form FDA 1571 was updated to add tracking fields for real-world evidence and real-world data (RWE/RWD) under the PDUFA VII commitments so sponsors submitting RWE/RWD will provide those new data elements.
Electronic Submission Requirement
FDA requires that the information for INDs be submitted electronically (forms are available electronically; printed forms can be requested and fees may apply), so sponsors and investigators must use electronic submission channels for IND-related forms.
Form 1571 Web Interface Available
FDA offers a new web-based interface for completing and electronically submitting Form FDA 1571 from mobile devices or desktops, which lets sponsors (including sponsor-investigators) fill out and submit IND applications online.
Right to Try Annual Report Deadline
Sponsors and manufacturers who provide an "eligible investigational drug" under the Right to Try Act must submit an annual report using Form FDA 5023 no later than March 31 each year, covering data for the preceding calendar year.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04937 — New Postal Products
The Postal Service wants to add or change special deals for competitive mail services, and the Postal Regulatory Commission is asking the public to share their thoughts by March 18, 2026. These changes could affect businesses using these mail services and might impact pricing or options soon. It’s a chance to weigh in on how mail deals evolve!
Next: 2026-04939 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements
The FDA is asking for public feedback on renewing rules that keep mammogram centers safe and reliable. These rules affect mammography facilities, making sure their equipment, staff, and practices meet high standards. Comments are due by April 13, 2026, and this process helps protect patients without adding extra costs.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in